Matches in Wikidata for { <http://www.wikidata.org/entity/Q89243536> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q89243536 description "artículu científicu espublizáu n'ochobre de 2014" @default.
- Q89243536 description "bài báo khoa học" @default.
- Q89243536 description "im Oktober 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89243536 description "scientific article published on 26 October 2014" @default.
- Q89243536 description "wetenschappelijk artikel" @default.
- Q89243536 description "наукова стаття, опублікована в жовтні 2014" @default.
- Q89243536 name "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 name "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 type Item @default.
- Q89243536 label "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 label "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 prefLabel "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 prefLabel "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 P1433 Q89243536-FE804811-A597-496E-9D69-1E0944E3F7B3 @default.
- Q89243536 P1476 Q89243536-4F439001-14BF-4A9C-A211-E4E981292DC4 @default.
- Q89243536 P2093 Q89243536-31694507-99DF-4401-86E9-C9F4E278D71B @default.
- Q89243536 P2093 Q89243536-AE86C94D-C640-40B7-B18B-1427ED8A8502 @default.
- Q89243536 P2093 Q89243536-E9021BCB-6A30-477B-81A1-5295A75194A0 @default.
- Q89243536 P304 Q89243536-6BE4E2BC-DED2-4FEC-8C38-14603AED4D1E @default.
- Q89243536 P31 Q89243536-E9AEB46C-7E82-4E07-B9B8-F3EA0E427542 @default.
- Q89243536 P356 Q89243536-12E1179A-1273-4AFB-B939-FA5F552B98E1 @default.
- Q89243536 P433 Q89243536-EF4B38E2-A2DC-440F-860A-F3EA612297F8 @default.
- Q89243536 P478 Q89243536-3BC58089-2A5D-4C16-B105-018216183161 @default.
- Q89243536 P577 Q89243536-BDCD8F38-A9B4-46C3-A77D-329B9136AE31 @default.
- Q89243536 P698 Q89243536-51E03BF8-071D-497A-B3EA-A211752B3F45 @default.
- Q89243536 P921 Q89243536-176783B1-0A2F-48FB-9433-1F59A0BD30B2 @default.
- Q89243536 P356 J.JVAL.2014.08.2350 @default.
- Q89243536 P698 27202332 @default.
- Q89243536 P1433 Q15766908 @default.
- Q89243536 P1476 "Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)" @default.
- Q89243536 P2093 "K Nørgaard" @default.
- Q89243536 P2093 "K Skaltsa" @default.
- Q89243536 P2093 "O Ghatnekar" @default.
- Q89243536 P304 "A648" @default.
- Q89243536 P31 Q13442814 @default.
- Q89243536 P356 "10.1016/J.JVAL.2014.08.2350" @default.
- Q89243536 P433 "7" @default.
- Q89243536 P478 "17" @default.
- Q89243536 P577 "2014-10-26T00:00:00Z" @default.
- Q89243536 P698 "27202332" @default.
- Q89243536 P921 Q34 @default.